254 related articles for article (PubMed ID: 30592031)
1. Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect.
Grimaux X; Delva R; Jadaud E; Croue A
Australas J Dermatol; 2019 Aug; 60(3):e235-e236. PubMed ID: 30592031
[No Abstract] [Full Text] [Related]
2. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA
Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab-associated bullous pemphigoid reactions involving multiple epitopes.
Aoki Y; Miyagawa F; Miyashita K; Nishimura Y; Hashimoto T; Asada H
Eur J Dermatol; 2019 Oct; 29(5):552-554. PubMed ID: 31570326
[No Abstract] [Full Text] [Related]
4. Bullous pemphigoid associated with the 480-mg nivolumab dose in a patient with metastatic renal cell carcinoma.
Palla AR; Smith E; Doll D
Immunotherapy; 2019 Oct; 11(14):1187-1192. PubMed ID: 31462105
[TBL] [Abstract][Full Text] [Related]
5. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.
Kuwatsuka Y; Iwanaga A; Kuwatsuka S; Okubo Y; Murayama N; Ishii N; Hashimoto T; Utani A
J Dermatol; 2018 Jan; 45(1):e21-e22. PubMed ID: 28944534
[No Abstract] [Full Text] [Related]
6. Dyshidrosiform pemphigoid due to nivolumab therapy.
Hayashi W; Yamada K; Kumagai K; Kono M
Eur J Dermatol; 2021 Jun; 31(3):411-412. PubMed ID: 34309527
[No Abstract] [Full Text] [Related]
7. Bullous pemphigoid developing upon immune checkpoint inhibition with nivolumab.
Grän F; Goebeler M; Gesierich A
Eur J Dermatol; 2019 Aug; 29(4):448-449. PubMed ID: 31625927
[No Abstract] [Full Text] [Related]
8. Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor.
Kwon CW; Land AS; Smoller BR; Scott G; Beck LA; Mercurio MG
J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e349-e350. PubMed ID: 28129461
[No Abstract] [Full Text] [Related]
9. Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid.
Sowerby L; Dewan AK; Granter S; Gandhi L; LeBoeuf NR
JAMA Dermatol; 2017 Jun; 153(6):603-605. PubMed ID: 28355425
[No Abstract] [Full Text] [Related]
10. Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid.
Ridpath AV; Rzepka PV; Shearer SM; Scrape SR; Olencki TE; Kaffenberger BH
Int J Dermatol; 2018 Nov; 57(11):1372-1374. PubMed ID: 29624655
[No Abstract] [Full Text] [Related]
11. Clinical and dermoscopical presentation of nivolumab-induced pemphigoid in a metastatic melanoma patient.
Chersi F; Conforti C; Zalaudek I; Bazzacco G; Zelin E; di Meo N
Melanoma Res; 2023 Jun; 33(3):262-263. PubMed ID: 37114722
[No Abstract] [Full Text] [Related]
12. Bullous pemphigoid exacerbated by nivolumab and temporally rescued with therapeutic plasma exchange.
Waki Y; Nobeyama Y; Chujo S; Asahina A
J Dermatol; 2024 May; 51(5):e149-e150. PubMed ID: 38010735
[No Abstract] [Full Text] [Related]
13. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
Front Immunol; 2022; 13():984132. PubMed ID: 36189265
[TBL] [Abstract][Full Text] [Related]
14. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
Aggarwal P
Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
[No Abstract] [Full Text] [Related]
15. Lichen planus pemphigoides developing from patient with non-small-cell lung cancer treated with nivolumab.
Sato Y; Fujimura T; Mizuashi M; Aiba S
J Dermatol; 2019 Oct; 46(10):e374-e375. PubMed ID: 31062404
[No Abstract] [Full Text] [Related]
16. Eruptive keratoacanthomas secondary to nivolumab immunotherapy.
Bednarek R; Marks K; Lin G
Int J Dermatol; 2018 Mar; 57(3):e28-e29. PubMed ID: 29318617
[No Abstract] [Full Text] [Related]
17. [A Case of Nivolumab-Induced Isolated Adrenocorticotropic Hormone Deficiency Presenting Dyspnea].
Ito K; Uchida T; Manabe Y; Miyazaki Y; Itoh H; Mishina M; Okuno H
Hinyokika Kiyo; 2018 Oct; 64(10):391-395. PubMed ID: 30543736
[TBL] [Abstract][Full Text] [Related]
18. Fatal Acute Motor Axonal Neuropathy Induced by Nivolumab: A Case Report and Literature Review.
Yildirim N; Gonen M; Balgetir F; Er MB
Clin Genitourin Cancer; 2019 Dec; 17(6):e1104-e1107. PubMed ID: 31471269
[No Abstract] [Full Text] [Related]
19. Immune checkpoint inhibitors myocarditis: not all cases are clinically patent.
Thibault C; Vano Y; Soulat G; Mirabel M
Eur Heart J; 2018 Oct; 39(38):3553. PubMed ID: 30107497
[No Abstract] [Full Text] [Related]
20. [A Case of Rheumatoid Arthritis Developed during Treatment with Nivolumab for Renal Cell Carcinoma].
Tomizawa M; Nakai Y; Maesaka F; Owari T; Hara R; Miyake M; Inoue T; Anai S; Tanaka N; Fujimoto K
Hinyokika Kiyo; 2018 Oct; 64(10):397-401. PubMed ID: 30543737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]